---
title: "Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298319347.md"
description: "Jefferies analyst Andrew Tsai maintained a Buy rating on Dyne Therapeutics with a $50 price target, citing its leading muscle disease platform, late-stage therapies for multibillion-dollar markets, and dual-path approval strategy. Stifel Nicolaus also issued a Buy rating with a $37 target. Both firms highlight strong clinical data and favorable risk-reward profiles despite recent competitor setbacks."
datetime: "2026-09-08T12:25:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298319347.md)
  - [en](https://longbridge.com/en/news/298319347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298319347.md)
generator: "portal-rs"
---

# Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy

In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on Dyne Therapeutics, with a price target of $50.00.

Andrew Tsai has given his Buy rating due to a combination of factors, principally Dyne’s emergence as a leading platform in muscle diseases with two late-stage, potentially best‑in‑class therapies. He believes the DM1 candidate z‑basivarsen and the DMD Exon 51 drug together target multibillion‑dollar markets, are already on an expedited regulatory path, and can still deliver strong outcomes despite a recent competitor’s Phase III setback.

Andrew Tsai’s rating is based on the view that Dyne’s ASO-based DM1 program shows more robust clinical and safety data than the failed siRNA competitor, while the DMD franchise offers substantial upside and diversification, including further exon targets. He also highlights that Dyne’s strategy of using vHOT for accelerated approval and then a separate functional endpoint trial gives the company two potential shots at full approval, supporting a favorable risk‑reward profile and significant upside into upcoming clinical and regulatory milestones.

Tsai covers the Healthcare sector, focusing on stocks such as Biogen, Definium Therapeutics, and BridgeBio Pharma. According to TipRanks, Tsai has an average return of 30.4% and a 60.99% success rate on recommended stocks. 

In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $37.00 price target.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders](https://longbridge.com/en/news/299274984.md)
- [DYN: Expect major regulatory and clinical milestones in DMD and DM1, with commercial launch preparations underway](https://longbridge.com/en/news/299076189.md)
- [Dyne Therapeutics grants new hires stock options for 278,100 shares, plus 88,400 restricted stock units](https://longbridge.com/en/news/299359973.md)
- [IONS: Breakthrough approvals and robust launches drive growth, with a deep pipeline advancing in CNS and metabolic diseases](https://longbridge.com/en/news/299192045.md)
- [Evommune updates pipeline and market outlook in presentation](https://longbridge.com/en/news/299056315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**